gracetx.com (GRCE): EV/EBITDA Multiple
Global instability and sanctions are hindering component imports and the distribution of unique Grace Therapeutics, Inc. (GRCE) medications in several countries. This EV/EBITDA chart, with a value of 0.00, links external risks to the company's small molecule development model for treating rare brain pathologies. Meanwhile, the approval potential for new formulas remains unclear, and the current share price already prices in weak financial performance.
Analytical breakdowns for gracetx.com (GRCE)
- current price and projected stock value:
- stock exchange capitalization data:
- issuer book value statistics:
- debt level and financial liquidity data:
- financial results and valuation multiples details:
GRCE - Net Profit|Expected Profit Grace Therapeutics, Inc.|GRCE - Market Cap to Net Income|Forward P/E Multiple Grace Therapeutics|GRCE - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio GRCE|GRCE - Operating profit EBITDA|Net earnings per share for the last 12 months Grace Therapeutics|GRCE - Earnings per share for the last four quarters|Quarterly EPS earnings growth gracetx.com|GRCE - Expected net earnings per share growth this year|Earnings growth forecast for next year Grace Therapeutics, Inc.
- revenue and sales details:
Summary company analysis:Grace Tx GRCE
EV/EBITDA compares the total enterprise value, including net debt, with operating profit before taxes and amortization, reflecting the actual value of assets relative to their ability to generate cash flow. By analyzing the EV/EBITDA multiple trend, an investor assesses the efficiency of drug repurposing for rare disorder therapies for Grace Therapeutics, Inc. (GRCE), taking into account the company's debt load when settling accounts with highly specialized clinics and insurance funds.
Competitor analysis
EV/EBITDA Multiple BIIB (Biogen Corp)|EV/EBITDA Multiple Neurocrine Corp NBIX|Regencell Bioscience - EV/EBITDA Multiple|axsome.com (AXSM) - Enterprise Value to EBITDA Ratio|ACAD: EV/EBITDA Multiple|Company Value to EBITDA Xenon Pharmaceuticals Inc. (XENE)|Enterprise Value to EBITDA Ratio VKTX|SUPN: Business Value to Operating Income Before Depreciation|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|Enterprise Value to Operating Income Before Depreciation Ratio DNLI|EV/EBITDA Multiple HRMY (Harmony Biosciences Holdings, Inc.)|Business Value to Operating Income Before Depreciation BHVN|Amylyx - EV/EBITDA Multiple|Company Value to EBITDA Trevi Corp|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|anavex.com - Business Value to Operating Income Before Depreciation|CBLL (CeriBell) - EV/EBITDA Multiple|EV/EBITDA Multiple Prothena Corporation PLC|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|ANNX: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple OMER (Omeros)|neurogene.com (NGNE) - Company Value to EBITDA|ACIU: Enterprise Value to EBITDA Ratio|VYGR - EV/EBITDA Multiple|NMRA (Neumora Therapeutics Inc) - Enterprise Value to EBITDA Ratio|SCLX: Enterprise Value to Operating Income Before Depreciation Ratio|TVGN (Tevogen Bio Holdings) - EV/EBITDA Multiple|Alpha Cognition Corp (ACOG) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple CGTX|Enterprise Value to EBITDA Ratio Inhibikase Therapeutics Inc IKT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cassava SAVA|Total Company Value to Operating Income Before Depreciation Ratio Assertio Holdings (ASRT)|COYA: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VTGN (Vistagen Therapeutics)|OVID: EV/EBITDA Multiple|ABOS - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CervoMed Inc|Enterprise Value to Operating Income Before Depreciation ATHE (Alterity Therapeutics Ltd)|EV/EBITDA Multiple CLNN|Enterprise Value to EBITDA Ratio pepgen.com PEPG|Jupiter Neurosciences - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Relmada Therapeutics Inc (RLMD)|Annovis Bio Corp - EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Firefly Neuro (AIFF)|anewmeds.com (KLTO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NeuroSense Therapeutics Ltd. - Business Value to Operating Income Before Depreciation|RVPH (Reviva Pharmaceuticals Holdings, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio MetaVia, Inc. (MTVA)|EV/EBITDA Multiple NRXS|HSDT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|NEUP: Enterprise Value to Operating Income Before Depreciation|Minerva Neurosciences, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Athira Pharma Inc|ADXN (Addex Therapeutics, Ltd.) - Enterprise Value to EBITDA Ratio|Alzamend Neuro (ALZN) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|PTIX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT - Company Value to EBITDA|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|Enterprise Value to EBITDA Multiple BrainStorm Cell Therapeutics Inc.|CARA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CHRO (chromocell.com)|ELYM: EV/EBITDA Multiple|Intra-Cellular Therapies, Inc. (ITCI) - EV/EBITDA Multiple|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Marinus Pharma (MRNS)|EV/EBITDA Multiple NKGN|NRBO - Company Value to EBITDA|Sage Therapeutics - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SNPX|TRVN: Enterprise Value to EBITDA Ratio|Vigil Neuroscience - Enterprise Value to Operating Income Before Depreciation Ratio|WENA: EV/EBITDA Multiple|cerevel.com - Business Value to Operating Income Before Depreciation
